^
    Back
    Association details:
    Biomarker:SLAMF8 overexpression
    Cancer:Gastrointestinal Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Transl Oncol
    Title:

    SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers

    Published date:
    10/26/2021
    Excerpt:
    Higher SLAMF8 expression was positively associated with CD8 expression and a better response to anti-PD1 treatment. We further observed dynamically increased expression of SLAMF8 in murine models relatively sensitive to anti-PD1 treatment….Higher SLAMF8 expression may predict better anti-PD1 immunotherapy efficacy in GI cancer.
    DOI:
    https://doi.org/10.1002/cti2.1347